Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7684A vs Pembrolizumab in First-Line PD-L1 Positive Metastatic NSCLC
NCT04738487Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Countries
- 23
01
Overview
A Phase 3 trial of vibostolimab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Apr 2021; status: terminated.
02
Drugs
vibostolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04738487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738487.